Arcutis Biotherapeutics, Inc.: how funds voted at the meeting of 12 Jun 2025
- Ticker
- ARQT
- Meeting
- Season
- year to 30 June 2025
- Filers reporting
- 311
- Ballot items
- 3
311 filers on Form N-PX reported votes at the Arcutis Biotherapeutics, Inc. meeting of 12 Jun 2025. The records fall into 3 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.
This meeting is in the year to 30 June 2025. The latest season on file is the year to 30 June 2026. The page of Arcutis Biotherapeutics, Inc. has the latest meeting.
If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.
The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .
The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.
The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.
The page gives records. It gives no investment advice and no advice on how to vote.
Season on this page: year to 30 June 2025. Filings read through . How the figures are made
The ballot
Item 1: Director elections
3 nominees. 43.0% of the reported votes are for. 80 filers withheld from or voted against at least one nominee.
542 vote records from 111 filers. 64 of the 111 filers that marked the item voted against management.
- Positions of 33 fund families
- For 13
- Abstain or withhold 20
- Against management 19
Item 2: Advisory vote on executive pay (say-on-pay)
421 vote records from 308 filers. 124 of the 298 filers that marked the item voted against management. 10 filers gave no management mark.
- Positions of 38 fund families
- For 22
- Against 16
- Against management 16
Item 3: Audit-related items (auditor ratification)
180 vote records from 110 filers. 1 of the 110 filers that marked the item voted against management.
- Positions of 33 fund families
- For 33
Positions of the fund families
A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.
KeyForAgainstAbstain or withholdSplit or no voteAgainst management
| Fund family | 2. Say-on-pay | 3. Auditor |
|---|---|---|
| AllianceBernstein | Against, against management | No report |
| American Century | Against, against management | For |
| BlackRock and iShares | For | For |
| BNY Mellon | Against, against management | No report |
| Brighthouse Funds | Against, against management | For |
| Charles Schwab | For | For |
| Columbia Threadneedle | Against, against management | For |
| DWS | Against, against management | For |
| Equitable | For | For |
| Federated Hermes | For | For |
| Fidelity | Against, against management | For |
| First Trust | Against, against management | For |
| Franklin Templeton | For | For |
| Global X | For | For |
| Goldman Sachs | For | For |
| Guggenheim and Rydex | Against, against management | For |
| Invesco | Against, against management | For |
| J.P. Morgan | For | For |
| John Hancock and Manulife | For | For |
| Lincoln Financial | For | For |
| Morgan Stanley, Eaton Vance and Calvert | Against, against management | For |
| Nationwide | For | For |
| Natixis and Loomis Sayles | For | No report |
| Neuberger Berman | For | No report |
| Northern Trust and FlexShares | For | For |
| Nuveen and TIAA | For | For |
| Pacific Life funds | For | For |
| PGIM and Prudential | For | For |
| Principal | Against, against management | For |
| ProShares and ProFunds | Against, against management | For |
| Russell Investments | For | No report |
| SEI | For | For |
| State Street and SPDR | For | For |
| T. Rowe Price | Against, against management | For |
| Vanguard | For | For |
| Victory Capital | Against, against management | For |
| Virtus | Against, against management | For |
| Voya | For | For |
Questions
- How many filers reported votes at the Arcutis Biotherapeutics, Inc. meeting?
- 311 Form N-PX filers reported votes at the meeting of 12 Jun 2025. On say-on-pay, 124 of 298 filers that marked the item voted against management (41.6%).
- Is this the result of the meeting?
- No. The page counts the filers that report on Form N-PX, and the shares they reported. Arcutis Biotherapeutics, Inc. reports the result of a vote on Form 8-K.
- Why does the page show counts only for director elections?
- A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Arcutis Biotherapeutics, Inc. with a meeting date within three days of 12 Jun 2025. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .